Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but some physicians recommend that their patients discontinue them during pregnancy.
Scientists at the University of Birmingham have found that increased male hormones result in women with polycystic ovaries having a two-fold increased risk of developing non-alcoholic fatty liver disease.
A new study in the Journal of Hepatology adds NAFLD to the list of diseases associated with a Western diet that includes relatively high consumption of red and processed meat
Long-term proton pump inhibitor (PPI) use does not increase the risk of hip fracture among persons with Alzheimer’s disease, according to a new study from the University of Eastern Finland. The risk of hip fracture was slightly increased for PPI use of less than one year, but not for long-term or cumulative use during a follow-up period of 10 years. In addition, there were no significant differences between PPI drug substances and the associated risk of hip fracture. The findings were published in Alimentary Pharmacology & Therapeutics.
Younger patients face highest risks
Proton pump inhibitors (PPIs)—medications commonly used to treat heartburn, acid reflux, and ulcers—have been linked with potentially serious side effects including a possible increased risk of bone fractures. In a new Alimentary Pharmacology & Therapeutics study, however, patients with Barrett’s eosophagus—a long-term complication of acid reflux— who took high doses of PPIs for prolonged periods were no more likely to have bone fractures or evidence of bone thinning (osteopenia or osteoporosis) than people in the general population.